Taken together, as HER2 amplification became a clinically relevant genetic alteration occurring in 3–5% metastatic CRC patients [58], it is imperative to understand the molecular determinants of dual HER2 blockade resistance which may strike as primary or acquired resistance [37, 62–64]. Here, ERBB2 is linked to colorectal carcinoma.